LEGN US52490G1022

Report

Delayed Nasdaq - 12/03 04:00:00 pm
44.39	USD		-8.78%

11/16	Legend Biotech's Loss Widens, Revenue Rises in Q3	MT
11/16	LEGEND BIOTECH : Reports Third Quarter 2021 Financial Results and Recent Highlights - Form 6-K	PU
11/16	Earnings Flash (LEGN) LEGEND BIOTECH Posts Q3 Loss $-0.43	MT

Summary

Quotes 5-day view Delayed Quote.

Delayed Nasdaq

11/29/2021	11/30/2021	12/01/2021	12/02/2021	12/03/2021	Date
54.11(c)	51.51(c)	49.84(c)	48.66(c)	44.39(c)	Last
557 133	4 681 196	500 600	519 719	559 110	Volume
-0.06%	-4.81%	-3.24%	-2.37%	-8.78%	Change

More quotes

Estimated financial data (e) (USD)

Sales 2021	66,6 M - -
Net income 2021	-402 M - -
Net cash position 2021	297 M - -
P/E ratio 2021	-30,8x
Yield 2021	-

Sales 2022	368 M - -
Net income 2022	-291 M - -
Net cash position 2022	335 M - -
P/E ratio 2022	-47,3x
Yield 2022	-

Capitalization	5 904 M 5 904 M -
EV / Sales 2021	84,2x
EV / Sales 2022	15,1x
Nbr of Employees	882
Free-Float	6,93%

More Financials

Company

Legend Biotech Corporation. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of cell therapies for oncology and other indications. Its lead product candidate, LCAR- B38M (cilta-cel), is an autologous CAR-T cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in a number of hematologic malignancies, including multiple...

Sector

Biotechnology & Medical Research

Calendar

12/11 | 05:30pm

Presentation

More about the company

Ratings of Legend Biotech Corporation

Trading Rating :

Investor Rating :

ESG Refinitiv :

More Ratings

All news about LEGEND BIOTECH CORPORATION

11/16	Legend Biotech's Loss Widens, Revenue Rises in Q3	MT
11/16	LEGEND BIOTECH : Reports Third Quarter 2021 Financial Results and Recent Highlights - Form..	PU
11/16	Earnings Flash (LEGN) LEGEND BIOTECH Posts Q3 Loss $-0.43	MT
11/16	Legend Biotech Reports Third Quarter 2021 Financial Results and Recent Highlights	BU
11/16	Legend Biotech Corporation Reports Earnings Results for the Third Quarter and Nine Mont..	CI
11/04	Genscript's Nasdaq-Listed Arm to Present 12 Sponsored Studies at American Society of He..	MT
11/04	Legend Biotech Showcases Updated and New Data from Comprehensive BCMA CAR-T, Cilta-Cel,..	PU
11/04	Legend Biotech Showcases Updated and New Data from Comprehensive BCMA CAR-T, Cilta-Cel,..	BU
11/04	Legend Biotech Showcases Updated and New Data from Comprehensive BCMA CAR-T, Cilta-Cel,..	CI
11/01	US FDA Extends Approval Target Date for Genscript Biotech's Myeloma Drug; Shares Fall 8..	MT
11/01	Legend Biotech Announces Extension of PDUFA Date for Cilta-Cel - Form 6-K	PU
11/01	Legend Biotech Announces Extension of PDUFA Date for Cilta-Cel	BU
11/01	Legend Biotech Announces Extension of PDUFA Date for Cilta-Cel	CI
10/28	Werewolf Therapeutics Appoints Meeta Chatterjee, Ph.D., to its Board of Directors	AQ
10/18	GENSCRIPT BIOTECH : Nasdaq-listed Arm to Present Preclinical, Clinical Trial Data of Cance..	MT

More news

News in other languages on LEGEND BIOTECH CORPORATION

11/16	La perte de Legend Biotech se creuse, mais les recettes augmentent au troisième trimest..
11/04	La branche de Genscript cotée au Nasdaq présentera 12 études parrainées lors du congrès..
11/01	La FDA américaine repousse la date cible d'approbation du médicament contre le myélome ..
10/18	La branche de Genscript Biotech cotée au Nasdaq présentera des données d'essais préclin..
09/23	L'unité de Genscript Bio cotée au Nasdaq organise la première journée de la recherche e..

More news

Analyst Recommendations on LEGEND BIOTECH CORPORATION

10/12	LEGEND BIOTECH : Morgan Stanley Adjusts Price Target on Legend Biotech to $51 From $50, Ma..	MT
05/18	LEGEND BIOTECH : BTIG Starts Legend Biotech at Buy with $55 Price Target	MT
04/19	LEGEND BIOTECH : Morgan Stanley Adjusts Legend Biotech's Price Target to $50 from $55, Kee..	MT

More recommendations

Provided by Scoopnest.com

Analysis

China's biotech sector comes of age with big licensing deals, global ambitions